{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:51:03Z","timestamp":1791888663485,"version":"4.3.4"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2]]},"abstract":"\n Background:<\/jats:title>\n Several studies have demonstrated that renal impairment not only decreases renal clearance but also hepatic clearance of medications that are CYP3A4 substrates. We evaluated the influence of renal function on the pharmacokinetics of antiepileptic drugs metabolized by CYP3A4.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n We retrospectively calculated the concentration\/dose ratio (CD ratio) for topiramate and clobazam in an epilepsy patient with renal impairment. In addition, we determined the CD ratio of perampanel in 17 patients with normal renal function and compared it with that in the patient with renal impairment.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n A patient with frontal lobe epilepsy and mild renal impairment [creatinine clearance (CCr): 67.7 mL\/min] was taking phenytoin and 3 CYP3A4 substrates (topiramate, clobazam, and perampanel). With progression of renal impairment (CCr: 28.1 mL\/min), the CD ratios of topiramate and clobazam increased by about 2-fold. The mean CD ratio of perampanel was 1740 \u00b1 966 ng\u00b7mL\u22121<\/jats:sup>\u00b7mg\u22121<\/jats:sup>\u00b7kg\u22121<\/jats:sup> in the 17 patients with normal renal function using phenytoin. By contrast, the CD ratio of perampanel was markedly higher (range: 5327\u20139113 ng\u00b7mL\u22121<\/jats:sup>\u00b7mg\u22121<\/jats:sup>\u00b7kg\u22121<\/jats:sup>) in the patient with renal impairment (CCr: <20 mL\/min).<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n These findings suggest that dose adjustment based on therapeutic drug monitoring is probably necessary when topiramate, clobazam, or perampanel is prescribed for patients with moderate-to-severe renal impairment.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000461","type":"journal-article","created":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T05:41:56Z","timestamp":1509687716000},"page":"144-147","source":"Crossref","is-referenced-by-count":13,"title":["Influence of Renal Function on Pharmacokinetics of Antiepileptic Drugs Metabolized by CYP3A4 in a Patient With Renal Impairment"],"prefix":"10.1097","volume":"40","author":[{"given":"Yoshiaki","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Clinical Research, National Epilepsy Center, NHO, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan;"},{"name":"Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences University of Shizuoka, Shizuoka, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotaka","family":"Usui","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Epilepsy Center, NHO, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Epilepsy Center, NHO, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Epilepsy Center, NHO, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitoshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Epilepsy Center, NHO, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan;"},{"name":"Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences University of Shizuoka, Shizuoka, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Epilepsy Center, NHO, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences University of Shizuoka, Shizuoka, Japan; and"},{"name":"Laboratory of Clinical Pharmacokinetics and Drug Safety, Shizuoka General Hospital, Shizuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Epilepsy Center, NHO, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/hep.1840380424","article-title":"Sex is a major determinant of CYP3A4 expression in human liver","volume":"38","author":"Wolbold","year":"2003","journal-title":"Hepatology"},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/clpt.1992.54","article-title":"Significant weight reduction in obese subjects enhances carbamazepine elimination","volume":"51","author":"Caraco","year":"1992","journal-title":"Clin Pharmacol Ther."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.1365-2125.2000.00314.x","article-title":"Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis","volume":"50","author":"Mayo","year":"2000","journal-title":"Br J Clin Pharmacol."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00134-011-2360-8","article-title":"Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients","volume":"38","author":"Kirwan","year":"2012","journal-title":"Intensive Care Med."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2165\/11534330-000000000-00000","article-title":"Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment","volume":"49","author":"Weil","year":"2010","journal-title":"Clin Pharmacokinet."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2165\/00003088-200847080-00003","article-title":"Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole","volume":"47","author":"Mallikaarjun","year":"2008","journal-title":"Clin Pharmacokinet."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00228-014-1719-5","article-title":"Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy","volume":"70","author":"Yamamoto","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/FTD.0000000000000367","article-title":"Effect of CYP inducers\/inhibitors on topiramate concentration: clinical value of therapeutic drug monitoring","volume":"39","author":"Yamamoto","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/FTD.0000000000000416","article-title":"Therapeutic drug monitoring for perampanel in Japanese epilepsy patients: influence of concomitant antiepileptic drugs","volume":"39","author":"Yamamoto","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/FTD.0000000000000274","article-title":"Perampanel serum concentrations in adults with epilepsy: effect of dose, age, sex, and concomitant anti-epileptic drugs","volume":"38","author":"Patsalos","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1194\/jlr.P040022","article-title":"Significant increase in plasma 4\u03b2-hydroxycholesterol concentration in patients after kidney transplantation","volume":"54","author":"Suzuki","year":"2013","journal-title":"J Lipid Res."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0009-9236(03)00056-0","article-title":"Characterization of hepatic cytochrome p450 3A activity in patients with end-stage renal disease","volume":"73","author":"Dowling","year":"2003","journal-title":"Clin Pharmacol Ther."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00228-014-1656-3","article-title":"The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients","volume":"70","author":"Lunde","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/bcp.12733","article-title":"CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease","volume":"80","author":"Suzuki","year":"2015","journal-title":"Br J Clin Pharmacol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201802000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:10:59Z","timestamp":1692051059000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201802000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000461","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}